MVP signs exclusive Penthrox deal for China
8 October 2018
MVP signs exclusive Penthrox deal for China with Daiichi Sankyo
Medical Developments International Limited (ASX: MVP) is delighted to announce it has entered into an exclusive Distribution and License Agreement with Daiichi Sankyo Company Limited (Daiichi Sankyo) for Penthrox® in China, Thailand and Vietnam. Daiichi Sankyo is listed on the Tokyo Stock Exchange (TSE: 4568)
Under the terms of the Agreement, Daiichi Sankyo will pay MVP up to $32.5 million US dollars (USD) (AUD $45.8m), including US$15 million upfront (AUD $21.1m), and sales-based milestone payments.
For further details please refer to the following link – ASX Announcement – (Penthrox – China)